Leadership Overview
Lilly has 10 executives leading key functions including strategy, technology, finance, marketing, and operations.
Driven by research and innovation, Lilly is dedicated to discovering, developing, manufacturing, and commercializing prescription medicines to improve global health outcomes.
Driven by research and innovation, Lilly is dedicated to discovering, developing, manufacturing, and commercializing prescription medicines to improve global health outcomes.
Leadership Roles at Lilly
Alison Dodd - Chief Executive Officer
Alison Dodd, the Chief Executive Officer at Lilly, directs the overarching corporate strategy and operational execution. Dodd guides the company's expansion into critical therapeutic areas, including diabetes, oncology, immunology, and neuroscience, ensuring alignment with Lilly's mission to create medicines that help people live longer, healthier, more active lives. Overseeing global operations, Dodd drives the company's commitment to research-driven innovation and patient access across international markets. This leadership role involves fostering a culture of scientific excellence and ethical conduct, crucial for navigating the complex biopharmaceutical landscape. By championing strategic partnerships and resource allocation, Alison Dodd ensures Lilly maintains its position as a leader in developing life-changing treatments and addressing unmet medical needs worldwide.
Pandurang Kulkarni - Chief Executive Officer, Aparito (Subsidiary of Eli Lilly) & Research Development Chief Analytics Officer & Senior VP, Stats, Data & Analytics
Pandurang Kulkarni, the Chief Executive Officer, Aparito (Subsidiary of Eli Lilly) & Research Development Chief Analytics Officer & Senior VP, Stats, Data & Analytics at Lilly, leads strategic analytics and data science initiatives. Kulkarni drives the development and implementation of advanced statistical models and data analysis techniques to accelerate drug discovery and development across Lilly's therapeutic areas. As CEO of Aparito, Kulkarni also oversees the integration of innovative data solutions within the subsidiary. This multifaceted role involves leveraging big data to uncover insights, optimize clinical trials, and enhance decision-making throughout the research and development process. Pandurang Kulkarni's leadership in analytics is fundamental to Lilly's commitment to scientific innovation and bringing new medicines to patients.
William Torres - Chief Financial Officer & Finance Administrative Manager
William Torres, the Chief Financial Officer & Finance Administrative Manager at Lilly, directs all financial operations and strategic fiscal planning. Torres oversees budgeting, forecasting, and capital allocation, ensuring robust financial health and supporting the company's extensive research and development investments in critical areas like oncology and immunology. This dual role also encompasses managing administrative functions within the finance department, promoting operational efficiency and compliance. By guiding investment strategies and managing financial risks, William Torres ensures Lilly can continue its mission of developing innovative medicines for global markets. The Chief Financial Officer's leadership is pivotal in sustaining Lilly's growth and its commitment to patient well-being through scientific advancement.
Kecia Patton - Vice President, Chief Financial Officer - Neuroscience Business Unit
Kecia Patton, the Vice President, Chief Financial Officer - Neuroscience Business Unit at Lilly, directs financial strategy and operations specifically for the neuroscience division. Patton oversees budgeting, financial analysis, and resource allocation, ensuring the unit's fiscal health and supporting its critical research and development efforts in neurological disorders. This specialized financial leadership is crucial for advancing Lilly's pipeline of innovative treatments for conditions like Alzheimer's disease and Parkinson's. By managing financial performance and identifying investment opportunities, Kecia Patton ensures the Neuroscience Business Unit can effectively pursue its goals. The Chief Financial Officer's focused financial oversight is instrumental in driving progress within this key therapeutic area.
Brandi Doyle - Vice President and COO- Lilly Cardiometabolic Health Development
Brandi Doyle, the Vice President and COO- Lilly Cardiometabolic Health Development at Lilly, oversees the operational execution and strategic development of the cardiometabolic health portfolio. Doyle manages the complex processes involved in bringing new treatments for diabetes and cardiovascular diseases from development to market, ensuring efficiency and quality. This operational leadership is critical for advancing Lilly's commitment to improving patient outcomes in these prevalent health areas. By optimizing development timelines and resource allocation, Brandi Doyle ensures Lilly can effectively deliver innovative solutions to patients globally. The COO's role is essential in driving the successful progression of the Cardiometabolic Health Development unit.
Venkat Thalladi - Vice President, Eli Lilly and Company. Chief Technology Officer, DICE Therapeutics
Venkat Thalladi, the Vice President, Eli Lilly and Company. Chief Technology Officer, DICE Therapeutics at Lilly, architects the technological vision and digital transformation initiatives. Thalladi spearheads the integration of advanced technologies across research, development, and commercial operations, enhancing efficiency and accelerating drug discovery pipelines. This role involves overseeing the technology strategy for both Lilly and its subsidiary, DICE Therapeutics, ensuring robust data analytics and cybersecurity measures are in place. By driving innovation in digital health solutions and platform development, Venkat Thalladi supports the company's focus on areas like diabetes, oncology, and neuroscience. The Chief Technology Officer's leadership ensures Lilly leverages cutting-edge technology to meet global patient needs and maintain a competitive edge in the biopharmaceutical industry.
Hongyun Zhao - Advisor, Bioanalysis and Chief Revenue Officer Management
Hongyun Zhao, the Advisor, Bioanalysis and Chief Revenue Officer Management at Lilly, provides strategic guidance on bioanalytical methodologies and revenue generation. Zhao's expertise supports the accurate assessment of drug efficacy and safety, critical for Lilly's development of new treatments in neuroscience and diabetes. This advisory role also involves optimizing revenue streams and market penetration strategies for Lilly's pharmaceutical portfolio. By ensuring rigorous bioanalytical standards and driving commercial success, Hongyun Zhao contributes significantly to the company's ability to bring life-changing medicines to patients worldwide. The Advisor's insights are crucial for maintaining Lilly's scientific integrity and market leadership.
Elizabeth van Gelder - Senior Director, Information Technology & Business Units & Special Projects Chief of Staff
Elizabeth van Gelder, the Senior Director, Information Technology & Business Units & Special Projects Chief of Staff at Lilly, orchestrates critical IT initiatives and manages special projects across business units. Van Gelder ensures seamless integration of technology solutions that support Lilly's research, development, and commercialization efforts in areas such as immunology and oncology. This role involves bridging the gap between IT operations and business objectives, driving efficiency and innovation. By overseeing key technology deployments and managing strategic projects, Elizabeth van Gelder enhances operational agility and supports the company's global mission to create medicines that improve lives. The Chief of Staff's leadership ensures effective execution of complex initiatives vital to Lilly's success.
Tracy Huang - Senior Secretary To Chief Information Officer
Tracy Huang, the Senior Secretary To Chief Information Officer at Lilly, provides essential administrative and operational support to the Chief Information Officer. Huang facilitates communication and workflow management within the IT department, ensuring the smooth execution of technology strategies that underpin Lilly's biopharmaceutical operations. This role is critical for maintaining organizational efficiency and supporting the CIO's leadership in areas such as data management and digital infrastructure. By managing schedules, coordinating meetings, and handling critical documentation, Tracy Huang ensures the IT department functions effectively to support Lilly's mission of developing innovative medicines. The Senior Secretary's diligent support is vital for the seamless operation of Lilly's technological backbone.
Christina Vega - VP-Head of Immunology, Oncology, and Neuroscience Division and Chief Marketing Officer
Christina Vega, the VP-Head of Immunology, Oncology, and Neuroscience Division and Chief Marketing Officer at Lilly, spearheads commercial strategies and market development for key therapeutic areas. Vega directs marketing initiatives, product launches, and brand management, ensuring Lilly's innovative treatments reach patients effectively. This leadership role encompasses driving growth and market share within the immunology, oncology, and neuroscience divisions. By translating scientific advancements into compelling market strategies, Christina Vega enhances patient access to life-changing therapies. The Chief Marketing Officer's expertise is vital in communicating the value of Lilly's medicines and reinforcing its position as a leader in addressing complex diseases.
Explore Leadership Teams in Manufacturing
Abbott is a global healthcare company that develops and delivers a broad range of medical technologies, diagnostics, nutrition products, and branded generic medicines. The company is focused on improving health outcomes and helping people live healthier lives across all stages of life. Its mission centers on creating innovative solutions that address important medical needs, including chronic disease management, cardiovascular care, diabetes care, and pain management.
Company Leadership SB
JA
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a fully integrated global essential medicines company powered by a robust U.S. generics business and a growing branded business as well as deepening portfolios in institutional injectables, biosimilars and select international markets. Together, were rapidly becoming one of the most dynamic, purpose-driven pharmaceutical companies delivering more affordable access to essential medicines. Today, Amneal is much more than generics. A series of strategic investments over the years has bolstered our world-class scientific rigor, production capabilities and commercial infrastructure. We have also invested substantially in our people through leadership development and employee well-being programs. Together, these advancements have accelerated our ability to deliver innovation, more complex products and broadened portfolios in new categories and geographies. Two decades after our founding, Amneal is better positioned than ever to deliver outcomes that meet important medical needs, make quality medicines more accessible and more affordable, and provide solutions for tomorrows health challenges. We are Amneal and We make healthy possible.
Company Leadership
AC
American Regent, Inc, a Daiichi Sankyo Group Company, develops, manufactures, and supplies high quality sterile injectables for healthcare providers, clinics and hospitals across the United States and Canada. We have locations in New York, Ohio, and Pennsylvania and sales territories nationwide.
Company Leadership
JB
JO
Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage each of its core therapeutic fields.
Company Leadership
MC
MA
AL
Frequently Asked Questions Regarding Lilly Top Executives and Leadership Team
Unlock more people and company data
